Rivaroxaban Chemical Profile: Precision in Molecular Design
Rivaroxaban (CAS: 366789-02-8), a highly selective direct Factor Xa inhibitor, stands as a cornerstone in modern anticoagulant therapy. With the molecular formula C₁₉H₁₈ClN₃O₅S and a molar mass of 435.88 g/mol , this small-molecule drug exemplifies structural ingenuity. Its crystalline solid form boasts high stability , with a melting point above 200°C , ensuring robustness in pharmaceutical formulations. The compound’s low solubility in water contrasts with its enhanced solubility in organic solvents , a trait optimized for bioavailability.
The architecture of rivaroxaban features a morpholine core linked to a chlorothiophene moiety , a design that maximizes binding affinity to Factor Xa while minimizing off-target effects. Its chiral center at the morpholine ring underscores the importance of stereochemistry in its anticoagulant efficacy—only the (R)-enantiomer exhibits therapeutic activity.
Rivaroxaban Applications: Beyond Thrombosis Prevention
Rivaroxaban’s primary claim to fame is its role in preventing venous thromboembolism (VTE) and stroke in atrial fibrillation . Unlike warfarin, it requires no routine monitoring , thanks to its predictable pharmacokinetics. Its oral bioavailability (~80-100%) and rapid onset of action (peak plasma concentration in 2-4 hours ) make it a patient-friendly alternative to traditional anticoagulants.
Following hip or knee replacement surgeries , rivaroxaban significantly reduces the risk of deep vein thrombosis (DVT) . Its once-daily dosing regimen improves compliance, a critical factor in post-operative care.
Recent studies explore rivaroxaban’s efficacy in cancer patients , who face elevated thrombosis risks due to hypercoagulability. Early data suggest it may outperform low-molecular-weight heparins in mortality reduction while offering the convenience of oral administration.
Beyond clotting prevention, rivaroxaban shows neuroprotective potential in preclinical models of ischemic stroke, possibly by mitigating thrombin-mediated neurotoxicity .
Innovation & Future Directions
Rivaroxaban’s success lies in its targeted mechanism —by inhibiting Factor Xa, it disrupts the coagulation cascade upstream, reducing bleeding risks compared to thrombin inhibitors. Ongoing research investigates its anti-inflammatory properties and potential in diabetic nephropathy , hinting at a broader therapeutic horizon.
Rivaroxaban Conclusion: A Paradigm Shift in Anticoagulation
From its meticulously crafted molecular structure to its life-saving clinical applications, rivaroxaban (CAS: 366789-02-8) epitomizes the synergy of medicinal chemistry and patient-centric design . As science uncovers new therapeutic niches, this anticoagulant continues to redefine standards in thrombosis management and beyond .
---
Key Features Highlighted:
- Molecular elegance : Chlorothiophene-morpholine synergy for selective Factor Xa inhibition.
- Versatile applications : Cardiovascular, orthopedic, oncology, and neurology.
- Future-ready : Expanding into anti-inflammatory and metabolic research.
